Aviragen Therapeutics (AVIR) Misses Q4 EPS by 5c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.40), $0.05 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Take-Two stock drops as GTA 6 leaks continue
• Clear Street Reiterates Buy Rating on Protagonist Therapeutics (PTGX)
• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $60 at H.C. Wainwright